Zoetis Inc. (ZTS) Enterprise Value (EV): $62.97B
The enterprise value (EV) for Zoetis Inc. (ZTS) is $62.97B as of Tuesday, June 9, 2026.
ZTS Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$62.97B
ZTS Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Zoetis Inc. (ZTS) | — | $62.97B |
| Centene Corporation (CNC) | $31.94B | $21.10B |
| IQVIA Holdings Inc. (IQV) | $31.09B | $52.94B |
| Agilent Technologies, Inc. (A) | $38.26B | $42.98B |
| DexCom, Inc. (DXCM) | $30.17B | $26.37B |
| Biogen Inc. (BIIB) | $29.00B | $29.76B |
| Veeva Systems Inc. (VEEV) | $27.37B | $32.05B |
| Humana Inc. (HUM) | $43.60B | $39.59B |
| Waters Corporation (WAT) | $24.19B | $23.51B |
| Mettler-Toledo International Inc. (MTD) | $23.50B | $31.01B |
Enterprise Value Calculation
Market Cap
$34.46B
Total Debt
$9.29B
Cash
$2.31B
Enterprise Value
$62.97B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Zoetis Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Zoetis Inc. (ZTS)?
- The enterprise value (EV) for ZTS stock is $62.97B.
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck